Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
about
Antibodies against Streptococcus agalactiae proteins c(alpha) and R4 in sera from pregnant women from Norway and ZimbabweGram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary TractMolecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococciSurface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope.Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein.Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype VAntibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.Reverse line blot assay for direct identification of seven Streptococcus agalactiae major surface protein antigen genesMolecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes.Streptococcus agalactiae alpha-like protein 1 possesses both cross-reacting and Alp1-specific epitopesIntranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.Multiplex PCR assay for direct identification of group B streptococcal alpha-protein-like protein genes.Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinAlpha C protein-specific immunity in humans with group B streptococcal colonization and invasive diseaseAssociation between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection.Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.Human Siglec-5 inhibitory receptor and immunoglobulin A (IgA) have separate binding sites in streptococcal beta protein.Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus.Sequence variability is correlated with weak immunogenicity in Streptococcus pyogenes M protein.Status of group B streptococcal vaccine development.
P2860
Q28362942-65617D7C-5B54-4E5B-A122-5CCA9AC4442DQ28829569-99134E4B-C7F4-4235-9835-2E995903F45EQ30799389-F8142422-3C0C-4598-A958-1B6E6BADB711Q33538951-DA19F9B3-6110-4415-A971-3B8965D20625Q33591531-18C067B5-A725-4CCE-945B-21FDF1EBC27CQ33715970-12949EBC-A938-4541-8B36-BE7BC01E7A29Q33719415-65339EB8-832C-43A1-BC9B-CFE9F09C566FQ33999955-DFBA89A1-C35D-4CCA-92EF-11B32B14C6C1Q34002706-71DB2867-F59F-4D13-883E-0F1C23E048DCQ34006819-4BBAA493-A3A3-48C2-9EAE-4E6FABC9B907Q34184513-1D6B4FB8-2DD8-4584-8F1A-F5BE0FC6214AQ34325853-A4E91446-9E1E-4D25-81C1-151D3F668431Q34945913-7B30B624-0B86-40AF-9E3C-2EB92CFAFDF2Q35138780-4C1EC398-7BEE-4EA7-A2AD-9BF2B985EEF8Q35550898-18FAAC4A-0DA6-42B4-80E7-F59D9CF79628Q35913598-E32BAC7A-8F48-4418-BCA6-F139353D8F19Q36600148-3258A456-7E93-449F-99F5-687809BFAE37Q36746962-5C288EE4-DE56-418D-8FF4-3DD38E4FDBEBQ36969532-AD7C4C0C-C25A-4203-979C-6C3FD9F48AADQ37168240-B20BB4A0-BE56-4730-93A5-E8D7F554EC95Q37258108-4B68D49B-C89E-4D7E-88C8-A86703E62FF4Q38674244-A4F02BD3-7CB2-4D12-8835-F413EC85D8FAQ39829516-DC600DD4-CBDE-4A82-A1C2-355F2E2B2C7AQ40736057-47B405F5-C82B-4B67-8D29-6090138292C8Q48041915-8629C46E-25B9-4DAD-9A34-3D825C64F5DE
P2860
Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Experimental vaccination again ...... urface proteins Rib and alpha.
@ast
Experimental vaccination again ...... urface proteins Rib and alpha.
@en
type
label
Experimental vaccination again ...... urface proteins Rib and alpha.
@ast
Experimental vaccination again ...... urface proteins Rib and alpha.
@en
prefLabel
Experimental vaccination again ...... urface proteins Rib and alpha.
@ast
Experimental vaccination again ...... urface proteins Rib and alpha.
@en
P2093
P2860
P1476
Experimental vaccination again ...... urface proteins Rib and alpha.
@en
P2093
Stålhammar-Carlemalm M
P2860
P304
P407
P577
1996-09-01T00:00:00Z